Data as of:
Price 01-14-26 16:00 ET,
Balance Sheet 2025-09-30,
Income Statement 2025-09-30,
Cash Flow 2025-09-30
Indicators
Dividend indicators
Value
Date
Pays Dividend
No
12-21-2025
Last Dividend Date
1-9-17
Income indicators
Value
Date
EBITDA Positive
No
12-21-2025
Net Income Positive
No
12-21-2025
Avg CA Burn (Annual %)
-41.89%
12-21-2025
Avg CA Burn (Quarterly %)
-12.19%
12-21-2025
Shares Outstanding Changes
Date
Shares Outstanding
Delta
No recent share changes
Interesting Volume Days
Date
Volume
Shares Outstanding
Volume / Shares
Price
2026-01-14
20,030,145
8,009,488
250.08%
$1.88
2026-01-13
405,498,282
8,009,488
5062.72%
$2.19
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM) at home. In addition, the company develops ultra-high concentration (UNO) that is in Phase 1 clinical trial to treat multiple solid and cutaneous tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions and autism spectrum disorder. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.